Kane Biotech (CVE:KNE) Reaches New 12-Month Low – Here’s What Happened

Kane Biotech Inc. (CVE:KNE)’s share price hit a new 52-week low during trading on Monday . The company traded as low as C$0.09 and last traded at C$0.09, with a volume of 60000 shares traded. The stock had previously closed at C$0.10.

Kane Biotech Stock Down 10.0 %

The company has a debt-to-equity ratio of -331.42, a quick ratio of 0.39 and a current ratio of 0.80. The business has a 50 day simple moving average of C$0.10 and a 200-day simple moving average of C$0.12. The firm has a market capitalization of C$12.97 million, a price-to-earnings ratio of 2.25 and a beta of 0.52.

Insiders Place Their Bets

In other Kane Biotech news, Director Marc Edwards bought 2,000,000 shares of Kane Biotech stock in a transaction on Friday, January 17th. The shares were bought at an average price of C$0.10 per share, for a total transaction of C$200,000.00. 37.21% of the stock is owned by insiders.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.